GlassScriptPhysician profile
Barbara Denise Pittman
NPI 1003208497
$8,557.94
in general payments reported to CMS, 2019-2025
29 companies · $1,783 in 2025
The $1,783 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,786 · 2022: $2,047 · 2023: $1,369 · 2024: $1,572 · 2025: $1,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,511 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,510.68 |
| Education | $213.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,485.41 | 2021-2025 | |
| Amgen INC. | $1,275.42 | 2021-2025 | Evenity, Otezla, Enbrel |
| Janssen Biotech, INC. | $1,088.88 | 2021-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $1,084.52 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $448.14 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $394.91 | 2021-2025 | Acthar |
| Horizon Therapeutics Plc | $382.98 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $361.87 | 2021-2025 | Lupkynis |
| Octapharma USA, INC. | $320.72 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
| Glaxosmithkline, LLC. | $263.20 | 2021-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $223.09 | 2022-2025 | Orencia |
| Genentech USA, INC. | $206.02 | 2021-2023 | Actemra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.56 | 2021-2024 | Ofev |
| Lilly USA, LLC | $124.82 | 2022-2024 | Taltz |
| Ani Pharmaceuticals, INC. | $117.77 | 2023-2024 | Purified Cortrophin Gel |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $102.26 | 2022-2025 | |
| Radius Health, INC. | $87.65 | 2021-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $86.31 | 2022-2025 | Saphnelo |
| Genzyme Corporation | $69.11 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $42.92 | 2024 | |
| Genentech, INC. | $31.48 | 2021 | |
| Organon LLC | $27.23 | 2025 | Renflexis, Hadlima |
| Daiichi Sankyo INC. | $24.89 | 2024 | Injectafer |
| Alexion Pharmaceuticals, INC. | $24.64 | 2021 | |
| Kyowa Kirin, INC. | $24.55 | 2025 | |
| Janssen Scientific Affairs, LLC | $24.51 | 2022 | |
| Tersera Therapeutics LLC | $22.42 | 2025 | Quzyttir |
| Ultragenyx Pharmaceutical INC. | $21.96 | 2022 | |
| Evoke Pharma, INC. | $18.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Pittman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.